
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is for people with diffuse large B cell lymphoma or follicular lymphoma that has come back after or continued to get worse during treatment.
The trial is now only open to people with follicular lymphoma. There are enough people with diffuse large B cell lymphoma taking part in the trial.
Doctors can treat diffuse large B cell lymphoma (DLBCL) and follicular lymphoma with chemotherapy, targeted cancer drug and a steroid such as prednisolone. If your lymphoma comes back, you might have the same treatment.
Tazemetostat is a targeted cancer drug. It blocks an that lymphoma cells need to grow and multiply. We know from
that tazemetostat could stop cancer cells from growing and maybe even kill them.
The researchers want to find out if it can help people with lymphoma. In this trial some people with DLBCL will have:
People with follicular lymphoma will have tazemetostat only.
The main aims of this trial are to find out:
The following bullet points list the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this trial if all of the following apply. You:
Who can’t take part
You cannot join this trial if any of these apply.
Cancer related
You:
Medical conditions
You:
Other
You:
Please note the trial team is no longer asking people with diffuse large B cell lymphoma to join the trial.
There are 2 parts to this trial.
The first part was a phase 1 trial to find the best dose of tazemetostat to give. This part is now closed.
The second part is a phase 2 trial. The trial team need 340 people to take part. There are 6 groups in this part. Some groups are now closed.
Tazemetostat is a tablet you take twice a day. You continue to take tazemetostat as long as it is helping and the side effects aren’t too bad.
You shouldn’t eat grapefruit or drink grapefruit juice for a week before starting tazemetostat. This is because they can affect how much tazemetostat is in your blood.
Prednisolone is a tablet. If you are in one of the groups taking prednisolone your doctor will tell you how many to take and how often.
Tissue and blood samples
The team will ask your permission to get a small sample of tissue from when you were first diagnosed.
When you agree to take part in the trial they will also ask for a sample of tissue (biopsy) taken from your lymphoma and, or a . You don’t have to agree to have these done. You can still take part in the trial.
Researchers will use these samples to find out more about lymphoma and what happens to tazemetostat in the body.
When you first start treatment, you have a blood sample taken on 3 separate occasions. They will use these samples to find out what happens to tazemetostat in the body.
You see the doctor before taking part to have some tests. These include:
For the first 8 weeks of treatment, you will see the doctor every 2 weeks for:
Then you see the doctor every 4 weeks for the same tests as above. Every 2 weeks a member of the team will phone you to see how you are.
You have the same scans you had a the beginning every 2 months for the first 6 months. Then every 3 months after that.
When you stop treatment, you see the doctor for:
After treatment a member of the trial team will phone you to see how you are and to ask if you have started any other treatment for your lymphoma.
Your doctor and nurse will monitor you closely for any side effects. Let your doctor or nurse know as soon as possible if:
Tazemetostat is a new drug and there might be side effects we don’t know about yet. The common side effects of tazemetostat we do know about from ongoing clinical trials include:
We have information about the side effects of prednisolone.
Your doctor or a member of the trial team will tell you about the side effects of tazemetostat and prednisolone before you agree to take part in the trial.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Peter Johnson
Epizyme, Inc.
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Freephone 0808 800 4040
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.